

EACR 2021 Virtual Congress

Call for Abstracts

Abstract submission deadline: **08 March 2021**

Abstracts can only be submitted [online](#).

Abstract Regulations

With the submission of an abstract to EACR 2021 Virtual Congress, the first author (presenting author):

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the congress.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published online by EACR on the Virtual Congress website and through the Virtual Congress Platform. EACR is not publishing abstracts in any Journal Supplement for this Congress. Submitted abstracts **cannot be withdrawn after 05 May 2021**.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
- Abstracts should be organised under the headings:
 - Introduction
 - Material and method

- Results and discussion
- Conclusion
- The online abstract submission procedure will **not** accept abstracts that exceed 2,500 characters (body of the abstract)
- Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.
- Supplementary data or appendices will not be accepted.
- Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black and converted to images and inserted as images.

Only the **submitting author** will receive a confirmation/abstract number by email from the EACR 2021 Virtual Congress Customer Service Team within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process, please contact our support team via: EACR2021@covr.be

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and virtual poster presentations by **06 April 2021**. The presenting author will receive an email with the result of the review and the Scientific Committee’s decision on the abstract. Depending on the selection of presentation format by the committee further instructions on how to upload posters, audio clips or presentation to the Virtual Congress Platform will be provided.

If a selected author cannot upload or present, the presenting author should assign a replacement presenter to present the abstract.

The following presentation formats are applicable for EACR 2021 Virtual Congress:

1. Oral presentation: the abstract is selected for oral presentation in a main Congress symposium
2. (Virtual) Poster: abstracts that have been selected for presentation in a virtual poster format. E-posters are grouped by main topic and will be displayed on the Virtual Congress platform as E-Posters. A 5-minute audio clip and a PDF poster can be uploaded to the Virtual Congress Platform.
3. Poster in the Spotlight session: in addition to a e-poster presentation as above a ‘mini oral’ presentation is given at a set time in the dedicated moderated Posters in the Spotlight Session.

Please note that if the abstract is accepted for oral or poster presentation, the abstract will only be published in the Virtual Congress platform abstract publications if one of the authors is a registered participant to the EACR 2021 Virtual Congress and full payment has been received by the advised deadline. If Congress registration has not occurred, the Abstract will not be included in the publications or visible on the Virtual Congress platform.

Abstract Submission

Abstract submission procedure

Abstracts must be submitted online by not later than **08 March 2021**, via the EACR 2021 Virtual Congress website.

Please follow the instructions on the screen.

Please note:

- When finished with the online submission, please click the “FINAL SUBMISSION” button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click “SAVE AND CLOSE”. This button allows you to update your abstract before final submission.
- After clicking “SAVE AND CLOSE”, your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click “FINAL SUBMISSION”. If you have not FINAL SUBMITTED your abstract by the **deadline of 08 March 2021** your abstract can not be accepted.
- Within 24 hours of submission, only the presenting author will receive a confirmation by email. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
- If you do not receive any confirmation, please contact eacr2021@covr.be within one week following the submission of the abstract.
- Submitting an abstract for EACR 2021 Virtual Congress does not constitute registration for the Congress. Abstract presenters must register to attend EACR 2021 Virtual Congress by following the instructions for registration on the EACR 2021 website.

For questions regarding the online submission process, please contact: eacr2021@covr.be

Only abstracts submitted online can be accepted. Abstracts submitted on paper or as email attachment will **not** be considered.

Topics for Abstract Submission

1. **CANCER CELL BIOLOGY**

Cell Proliferation/cell cycle
Cell Death / Autophagy
Oncogenes and Tumour Suppressor Genes
Metastases and EMT
Aging and Cancer
Senescence
Cancer Cell Metabolism
Cancer Initiating Cells / Cancer Stem Cells

2. **CANCER GENOMICS**

Genomic Alterations in Cancer
Functional Genomics
High-throughput sequencing
Genomic profiling of tumors
Large-scale approaches to cancer gene discovery

3. **EPIGENETICS**

DNA methylation
Epigenetic changes as molecular markers of cancer
Epigenomics
Histone modification
Epigenetic mechanisms and gene silencing
Chromatin structure and function

4. **BIOINFORMATICS AND COMPUTATIONAL BIOLOGY**

Application of bioinformatics to cancer biology
Artificial intelligence and machine learning
New algorithms and new software for data analysis
Mathematical modeling and statistical methods
Molecular modeling
Database resources and Network biology
Omics technologies

5. **TUMOR EVOLUTION AND HETEROGENEITY**

Causes and consequences of tumor heterogeneity
Methods to measure tumor evolution and heterogeneity
Drug resistance and clonal evolution

6. DRUG RESISTANCE

- Novel mechanisms
- Regulation of gene expression in drug resistance
- Reversal of drug resistance
- Drug transport and metabolism
- Resistance to immune checkpoint blockade and other immune based therapies

7. BIOMARKERS IN TISSUE AND BLOOD

- Liquid biopsies: Circulating DNA
- Liquid biopsies: Circulating tumor cells
- Diagnostic biomarkers
- Prognostic biomarkers
- Biomarkers predictive of therapeutic benefit
- Early detection biomarkers

8. SIGNALING PATHWAYS

- Receptors and Signal Transduction
- Gene Expression, Transcriptional Regulation
- Systems biology
- Computational models of biological systems

9. CARCINOGENESIS

- Mutagenesis, Carcinogen Metabolism
- Promotion and Progression
- DNA Damage and Repair
- Viral Oncogenesis

10. TRANSLATIONAL RESEARCH

- Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
- Molecular pathology
- Imaging
- Clinical Phase I/II trials with targeted drugs and novel agents
- Bioinformatics in therapies and clinical trials
- Infrastructures (biobanks, databases, genomic resources, others)

11. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS

- Drug Discovery / Drug Design
- Novel Targets, Delivery Systems
- Mechanisms of Drug Action, Drug Profiling
- New Therapies
- Pharmacogenetics and therapeutic response
- Pharmacogenomics
- Pharmacokinetics

Precision medicine
Target degradation

12. TUMOUR IMMUNOLOGY

Tumour Immunology
Immune Suppression and Escape
Tumour antigens and immune effectors
Oncogenic pathway-mediated deregulation of tumor immunity
Antigen processing and presentation
Microbiome and cancer

13. IMMUNOTHERAPY

Adoptive cell therapy
Immune response to therapies
Immunomodulatory agents and interventions
Therapeutic antibodies, including engineered antibodies
Vaccines
Immune checkpoints
Immune mechanisms invoked by other therapies including CARs

14. RADIOBIOLOGY / RADIATION ONCOLOGY

Tumour Cell Sensitisation to Radiotherapy
Radiation-activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational radiation research

15. MOLECULAR AND GENETIC EPIDEMIOLOGY

Risk Factors
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

16. PREVENTION and EARLY DETECTION

Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer

17. TUMOUR BIOLOGY

Animal models of cancer
Genetic and genomic instability
Tumour Progression: Invasion and Metastasis

Tumour Microenvironment

Tumour Angiogenesis

Tumour Inflammation

RNA biology in cancer (splicing, noncoding RNAs, RNA modifications) and therapy response